Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab: A Double-Blinded Prospective Observational Pilot Study

Trial Profile

Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab: A Double-Blinded Prospective Observational Pilot Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 19 May 2015 Planned End Date changed from 1 Feb 2017 to 1 Dec 2019 as per ClinicalTrials.gov record.
    • 19 May 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Dec 2019 as per ClinicalTrials.gov record.
    • 26 Aug 2011 Planned end date changed from 1 Nov 2015 to 1 Feb 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top